| abstract |
The present invention relates to deglycosylated monoclonal antibodies that bind amyloid beta (Abeta). The invention provides such antibodies and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the deglycosylated antibodies of the invention. |